Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99Tc-MDP vs Fosamax in Postmenopausal Women with DTC and Osteoporosis
NCT02304757Completed
- Sponsor
- Xinhua Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of technetium-99m-methylene diphosphonate in osteoporosis (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Percent Change of Bone Mineral Density in Lumbar and Hip at 12 months. Started Jan 2015; status: completed.
02
Drugs
technetium-99m-methylene diphosphonate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02304757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304757.